Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis

Acta Haematol (2018) 139 (3): 164–165.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report

Clelia Madeddu
Elisabetta Sanna
Sonia Nemolato
Olga Mulas
Sara Oppi
Mario Scartozzi
Giorgio La Nasa
Antonio Maccio

Diagnostics (2022) 12 (8): 1910.

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Novella Pugliese
Claudia Giordano
Davide Nappi
Luigiana Luciano
Claudio Cerchione
Mario Annunziata
Beniamino Casale
Elena Crisà
Maria Rosaria Villa
Luca Pezzullo
Maria Iovine
Marco Picardi
Francesco Grimaldi
Fabrizio Pane
Vincenzo Martinelli

Cancer Medicine (2019) 8 (6): 2802.

COMBINATION THERAPY FOR MYELOFIBROSIS

I. V. Gribkova
Yu. A. Oleinik
S. A. Shalaev
M. V. Davydovskaya
K. A. Kokushkin

Russian journal of hematology and transfusiology (2019) 64 (2): 188.

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

Massimo Breccia
Luigiana Luciano
Novella Pugliese
Elena Rossi
Mario Tiribelli
Emilia Scalzulli
Massimiliano Bonifacio
Bruno Martino
Roberto Latagliata
Giulia Benevolo
Giovanni Caocci
Gianni Binotto
Vincenzo Martinelli
Michele Cavo
Fabrizio Pane
Valerio De Stefano
Robin Foà
Francesca Palandri

Annals of Hematology (2019) 98 (8): 1933.